Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F16IL2 + Low-dose Cytarabine in Relapsed AML Post-alloHSCT
NCT02957032Phase 1Terminated
- Sponsor
- Philogen
- Start
- Apr 2016
- Primary completion
- Sep 2023
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of teleukin in acute myeloid leukemia (AML), sponsored by Philogen. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Apr 2016; status: terminated.
02
Drugs
teleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02957032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957032.